IRF2BP2 and acute myeloid leukemia: Overexpression of IRF2BP2 in the liver inhibits liver cancer induced by Hippo pathway inactivation.[42] IRF2BP2 was marked by an SE in AML samples, consistent with its high level of expression in AML.[43] Large‐scale CRISPR library screenings have shown that AML leukemia cells depend on IRF2BP2, and its disruption leads to an imbalance in inflammatory cytokine homeostasis, ultimately causing AML cell death.